Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies
Abexinostat added to pazopanib shows extended tolerability and long-term responses and survival. PBMC HDAC2 levels, the abexinostat target, are relevant predictors of response. In addition, metabolomic assessment points to kynurenine as a predictor for exceptional response to combined VEGF plus HDAC inhibition.
Authors
- Jennifer A. Grabowsky (ORCID: https://orcid.org/0000-0003-4871-0741)
- Erica S. Tsang (ORCID: https://orcid.org/0000-0003-2317-2721)
- Emily K. Bergsland (ORCID: https://orcid.org/0000-0001-7754-6552)
- Nela Pawłowska
- Susan Calabrese
- Rahul Aggarwal (ORCID: https://orcid.org/0000-0001-7003-7982)
- Pamela N. Münster (ORCID: https://orcid.org/0000-0002-2074-0984)
- Sibapriya Chaudhuri
- Mallika Sachdev Dhawan
- Scott Thomas
- Alexandrine Rozie
Institutions
- University Health Network (CA)
- University of California, San Francisco (US)
- Princess Margaret Cancer Centre (CA)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1200/po.24.00328
- Citations
- 3
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.70